1.54
+0.11(+7.69%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.44 |
| Day High | 1.56 |
| Day Low | 1.41 |
| 52-Week High | 3.45 |
| 52-Week Low | 1.23 |
| Volume | 1.63M |
| Average Volume | 1.37M |
| Market Cap | 435.4M |
| PE | -1.95 |
| EPS | -0.79 |
| Moving Average 50 Days | 1.85 |
| Moving Average 200 Days | 2.49 |
| Change | 0.11 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $88.35 as of March 12, 2025 at a share price of $1.54. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $140.38 as of March 12, 2025 at a share price of $1.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 31, 2025 1:00 PM GMT
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 1:00 PM GMT
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 05, 2024 1:00 PM GMT
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to